FDA Approves Hemophilia B Second Gene Therapy.

Published Date: 29 Apr 2024

Standard prophylactic factor IX was found to be noninferior to one dose of fidanacogene elaparvovec.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

We Don't Always Know What's 'Best' for Our Patients

2.

Best foot forward—chemo care should include podiatry, say researchers

3.

Radiation from CT scans could account for 5% of all cancer cases a year, study suggests

4.

In Relapsed/Refractory Myeloma, Blenrep-Based Regimen Produces PFS Advantage.

5.

investigating radiation oncology applications of artificial general intelligence.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot